The controlling interest in JSIM was acquired through two of Aida Pharmaceutical Inc.'s subsidiaries, namely Hangzhou Aida Pharmaceutical Co., Ltd. (which acquired a 43% equity interest) and Changzhou Fangyuan Pharmaceutical Co., Ltd. (which acquired a 55% equity interest).
JSIM is a national leader in microbiology with over thirty years of
research history. It is located in Wuxi City in
About Aida Pharmaceuticals, Inc.
Aida Pharmaceuticals, Inc. is a product-focused pharmaceuticals company
engaged in the formulation, clinical testing, registration, manufacture, sales
and marketing of advanced pharmaceutical and genetic products in mainland
For additional information, please visit http://en.aidapharma.com.
Contact Information:
Ashley Hull
(310) 450-9100 opt 1
ashley@leacapital.com
Broker Contact:
Chesapeake Group
(410) 825-3930
Safe Harbor Statement Under The Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.
SOURCE Aida Pharmaceuticals, Inc.